These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37726419)

  • 1. Dabrafenib-trametinib is effective in paediatric high-grade glioma.
    Romero D
    Nat Rev Clin Oncol; 2023 Nov; 20(11):734. PubMed ID: 37726419
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabrafenib-trametinib moves to the first line in low-grade glioma.
    Romero D
    Nat Rev Clin Oncol; 2023 Dec; 20(12):817. PubMed ID: 37816934
    [No Abstract]   [Full Text] [Related]  

  • 3. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
    Giorgis O; Doz F
    Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
    [No Abstract]   [Full Text] [Related]  

  • 5. Discrepancy in responses to dabrafenib plus trametinib combination therapy in intracranial and extracranial metastases in melanoma patients.
    Kobayashi T; Matsumoto S; Shimizu K; Miyake M; Maeda S; Hamaguchi Y; Matsushita T
    J Dermatol; 2021 Feb; 48(2):e82-e83. PubMed ID: 33161591
    [No Abstract]   [Full Text] [Related]  

  • 6. Dabrafenib Effective in Pediatric Glioma.
    Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 12. BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.
    Kiyohara T; Nagano N; Miyamoto M; Shijimaya T; Nakamaru S; Makimura K; Tanimura H
    Clin Exp Dermatol; 2019 Dec; 44(8):945-946. PubMed ID: 30950075
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
    González-Barrallo I; Castellón Rubio VE; Medina J; España S; Mujika K; Majem M; Aguado C; Cabrera Suárez MÁ; Palacio I; Osterloh L; Martínez-Fernández A; García-Castaño A
    Melanoma Res; 2022 Oct; 32(5):343-352. PubMed ID: 35762583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy.
    Muto Y; Fujimura T; Kambayashi Y; Ohuchi K; Amagai R; Okuma T; Furudate S; Hashimoto A; Aiba S
    Dermatol Ther; 2020 Nov; 33(6):e14430. PubMed ID: 33078860
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of full-dose dabrafenib and trametinib combination therapy in a patient on hemodialysis with metastatic melanoma.
    Hayakawa K; Wakimoto H; Mae K; Irisawa R; Harada K
    Int J Dermatol; 2021 Apr; 60(4):516-517. PubMed ID: 33165909
    [No Abstract]   [Full Text] [Related]  

  • 17. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
    Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
    Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
    [No Abstract]   [Full Text] [Related]  

  • 20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.